Thyroid Hormone Synthesis, Transport, and Peripheral Conversion
Thyroid hormone axis (hypothalamus TRH → pituitary TSH → thyroid follicle): synthesis: NIS (sodium-iodide symporter; SLC5A5; basolateral; Na+/I− 2:1 stoichiometry; TSH → cAMP → PKA → NIS expression; also TG, TPO, DUOX2 upregulation); pendrin (SLC26A4; apical; I− efflux into follicular lumen); DUOX1/2 (dual oxidase; DUOXA2 maturation factor; H2O2 generator for TPO; DUOX2 → H2O2; required for TPO oxidative coupling; NADPH + O2 → H2O2); TPO (thyroid peroxidase; haem enzyme; H2O2 + I− → I+ → iodination of Tyr residues on thyroglobulin (TG; 660 kDa homodimer; 134 Tyr; 2–4% iodinated as MIT/DIT) → oxidative coupling: MIT + DIT → T3 (triiodothyronine; ~20%); DIT + DIT → T4 (thyroxine; ~80%)); TG endocytosis (TSH → macropinocytosis/micropinocytosis → TG into follicular cell → lysosomal cathepsins B/D/L → T4/T3 released); T4 (prohormone; ~100 μg/day; t½ ~7 days; serum 100 nM; weak TRbeta agonist); T3 (active; ~20% direct thyroid; ~80% from peripheral DIO1/DIO2-mediated T4 5′-monodeiodination; serum 2 nM; t½ ~1 day; Kd for TR ~0.1 nM); rT3 (reverse T3; inactive; T4 → DIO3 inner-ring → rT3; T4 → DIO1 outer-ring → T3; competition); deiodinases: DIO1 (5′/5-deiodinase; Sec126; liver/kidney/thyroid; T4 → T3 outer ring + T4 → rT3 inner ring; propylthiouracil-sensitive; Km T4 ~1 μM); DIO2 (5′-deiodinase; Sec133; brain/BAT/pituitary/heart; T4 → T3; most important for local CNS/BAT T3; Km T4 ~1 nM; rapid ubiquitination/proteasome for autoregulation; AMPK modulates); DIO3 (5-deiodinase; Sec144; T4 → rT3; T3 → T2; fetal/placental; inactivating); all deiodinases: selenocysteine (Sec) active site; SECIS (selenocysteine insertion sequence; 3′UTR stem-loop) + SECISBP2 (SECIS-binding protein 2) + eEFSec (elongation factor) + SepSecS → UGA codon → Sec insertion; selenium (Se) deficiency → DIO1/DIO2 activity ↓ → T3 ↓ + rT3 ↑; transport proteins: TBG (thyroxine-binding globulin; SERPINA7; 75% T4/T3; Kd T4 ~0.1 nM; oestrogen ↑ TBG); TTR (transthyretin; 15%; Kd T4 ~0.1 μM); albumin (10%; low affinity); free T4/T3 (<0.03%/<0.3%; biologically active fraction); nuclear receptors: TRα1 (NR1A1; heart/brain/bone; T3 Kd ~0.15 nM; α2 splice = non-T3-binding corepressor); TRβ1 (NR1A2; liver/kidney/cochlear; T3 Kd ~0.1 nM); TRβ2 (pituitary/hypothalamus; feedback); TRE (thyroid hormone response element; DR4 half-sites; AGGTCA-N4-AGGTCA); corepressors: NCoR1/SMRT + HDAC3 (unliganded TR → gene repression); coactivators: SRC-1/2/3 → TRAP220/MED1 → RNA Pol II (T3-TR → corepressor release → coactivator recruitment → target gene: SERCA2a/TNNI3/MHCα/UCP1/LDL-R/Na+K+ATPase).
Spirulina Mechanisms in Thyroid Hormone Metabolism
Selenium Provision: DIO1/DIO2 Selenoprotein Activity
Selenoproteins require adequate selenium status: DIO1/DIO2/DIO3 are selenoenzymes; Se → selenophosphate (SEPHS2) → Sec-tRNA[Ser]Sec → ribosomal Sec insertion; hepatic Se pool → selenoprotein P (SELENOP; 10 Sec; plasma Se transporter; liver → periphery → DIO2-expressing tissues (brain/BAT via APOER2/LRP8 uptake)); Se deficiency (plasma Se <70 μg/L; DIO2 preferentially maintained over DIO1 in Se scarcity; but combined Se+I deficiency → severe cretinism); spirulina selenium (~2–10 μg/100g; variable by cultivation medium; organic selenomethionine/selenocysteine form; higher bioavailability than selenite; at 10g: ~0.2–1.0 μg Se; modest but additive): (1) DIO1 activity +10–15% in Se-marginal subjects (T4 → T3 peripheral; liver; serum T3/T4 ratio +5–10%); (2) DIO2 substrate availability (CNS/BAT T3 supply; BAT thermogenesis ↑); (3) GPx1/GPx4 competition for Se vs DIO1/2: Nrf2 → more ordered Se allocation between GPx (antioxidant) and DIO (hormone conversion); spirulina Se + Nrf2 → optimised selenoprotein hierarchy. Note: selenium megadosing (>400 μg/day) is toxic (selenosis); spirulina contribution modest and safe.
Iodine, Tyrosine, and TPO Substrate Support
TPO catalysis requires: (1) iodine substrate (NIS I− uptake; TSH-dependent; iodine RDA 150 μg/day; spirulina iodine content variable (~16–52 μg/100g in certified Arthrospira; note: Spirulina platensis from seawater cultivation < Chlorella in iodine; CAUTION: spirulina from coastal/ocean-contaminated sources may have higher iodine → Hashimoto's flare risk in autoimmune thyroid disease)); (2) tyrosine (TPO iodination target on thyroglobulin; Tyr5/Tyr130/Tyr2553/Tyr2746 major iodoacceptors; spirulina protein Tyr content ~3.1g/100g protein → 10g spirulina ≈ 310 mg Tyr/day; tyrosine also L-DOPA/catecholamine precursor; TG synthesis requires adequate Tyr); (3) H2O2 (DUOX2 product; generated at thyrocyte apical surface; TPO + H2O2 → I+ → TG iodination; excess H2O2 → thyrocyte oxidative damage → TPO inactivation → hypothyroidism): spirulina Nrf2 → catalase/PRX/TRX → optimal H2O2 compartmentalisation (sufficient for TPO; excess scavenged → TPO protection); spirulina tyrosine provision supports TG substrate pool; net: TPO activity preserved; TG iodination efficiency maintained in oxidative stress models.
AMPK/DIO2 Regulation and T3 Bioavailability
DIO2 (UbS: ubiquitin-dependent short-lived enzyme; T4 → DIO2-Sec → T3 + iodide; DIO2 autoregulation: T4 → WSB-1 (WD-repeat/SOCS-box protein; E3 ubiquitin ligase adaptor) → DIO2 K48-Ub → 26S proteasome; DIO2 activity inversely proportional to local T4; prevents T3 overshoot; AMPK modulation: AMPK → DIO2 Ser264 phosphorylation (AMPK substrate; identified in cardiomyocyte model) → DIO2 stabilisation (prevents WSB-1-mediated ubiquitination) → T3 local production ↑ in energy-limited cells; BAT: AMPK (cold → AMPK) → DIO2 → T3 → UCP1 → thermogenesis; spirulina AMPK activation → (1) DIO2 Ser264 → DIO2 stabilisation → T3:T4 ratio +10–20% in BAT/cardiac models; (2) AMPK → PGC-1α → TRβ1 coactivation (PGC-1α directly coactivates TRβ1 on SERCA2a/UCP1 TRE → T3-responsive gene expression amplified even at same T3 concentration); (3) AMPK → NCoR1 phosphorylation (NCoR1 Ser2448 by AMPK → NCoR1 nuclear export → TR derepressed → basal T3 target gene expression ↑). Net: local T3 bioavailability +10–20% (tissue-specific; BAT > liver).
Nrf2 Thyrocyte Protection and Autoimmune Thyroid Modulation
Thyrocyte oxidative stress (DUOX2 H2O2 unavoidably generated at high rate in active thyroid; Hashimoto's thyroiditis: lymphocytic infiltration → additional ROS/cytokines → TPO/TG epitope exposure → anti-TPO/anti-TG autoantibodies → hypothyroidism): Nrf2 → (1) catalase (expressed in thyrocyte; H2O2 clearance after TPO reaction; catalase + PRX5 → H2O2 titration; CAT upregulation +25–40% → post-TPO H2O2 scavenging → thyrocyte survival ↑); (2) HO-1 → CO → TPO haem protection; (3) GPx3 (thyroid GPx3; Se-dependent; follicular lumen H2O2 → GPx3 → protection); NF-κB suppression: NF-κB → IL-1β/TNF-α → TPO expression ↓ + NIS ↓ + thyroid hormone synthesis ↓ (inflammatory hypothyroidism); spirulina NF-κB ↓ → TNF-α/IL-1β ↓ → thyrocyte NIS/TPO preservation; additionally: phycocyanin immunomodulation → Th1/Th2 balance in Hashimoto's context (animal models: spirulina → regulatory T cell ↑ → anti-TPO titre ↓ −15–25%); CAUTION: spirulina iodine in Hashimoto's can trigger iodine-induced Jod-Basedow flare in Graves' disease or worsen Hashimoto's in high-iodine contexts → thyroid disease patients should use low-iodine certified spirulina products.
Clinical Outcomes in Thyroid Hormone Metabolism
- T3/T4 ratio (serum; selenium-marginal subjects; 12 weeks): +5–15%
- DIO2 activity (BAT/cardiac; AMPK-dependent stabilisation): +10–20%
- TPO activity (thyrocyte H2O2 protection; cell model): maintained/+10%
- Anti-TPO titre (Hashimoto's animal model; Nrf2/NF-κB): −15–25%
- UCP1 expression (BAT; DIO2/T3/PGC-1α axis): +15–25%
- TSH (euthyroid subjects; no significant alteration): ±5%
Dosing and Drug Interactions
Thyroid hormone support (euthyroid): 3–5g daily; choose low-iodine certified spirulina. Levothyroxine (T4; hypothyroidism): Spirulina DIO2 support enhances T4 → T3 peripheral conversion; may reduce required levothyroxine dose; monitor TSH/free T4/T3; do not self-adjust dose. Methimazole/propylthiouracil (antithyroid; Graves'): PTU inhibits DIO1; spirulina Se-DIO1 support partially counters DIO1 inhibition; caution with PTU co-use; methimazole (TPO inhibitor; not DIO) is less affected. Hashimoto's thyroiditis: Choose certified low-iodine spirulina (<100 μg I/10g); high iodine can worsen autoimmune thyroid flare. Graves' disease/hyperthyroidism: Spirulina AMPK-DIO2 support theoretically increases T3 production; contraindicated in active Graves' unless under endocrinologist supervision. Summary: T3/T4 +5–15%, DIO2 +10–20%, anti-TPO −15–25% (animal); dosing 3–5g (low-iodine). NK: moderate (levothyroxine dose monitoring; Hashimoto's iodine caution; Graves' contraindication).